Aimovig™

Random entry RSS

Posted in:
News

Lilly Announces Positive Results for Galcanezumab in Treating Episodic Cluster Headaches
By Seth Cockrum May 25, 2018 Comments are off
Last week, Eli Lilly and Company (“Lilly”) announced that galcanezumab met its primary endpoint in a Phase 3 study of patients with...

Read more

Tagged with: Aimovig™, Alder Biopharmaceuticals, Amgen, Eli Lilly, eptinezumab, erenumab, FDA, fremanezumab, galcanezumab, News, Novartis, Teva

http://twitter.com/share?text="[TITLE]&url=[PERMALINK]
ShareEmail, Linked In, Twitter, Facebook, Google Plus
Posted in:
News

Novartis and Amgen Announce FDA Approval of Aimovig™
By Seth Cockrum May 23, 2018 Comments are off
Last week, Novartis and Amgen announced the FDA approved Aimovig™ (erenumab) for the preventive treatment of migraine in adults. The...

Read more

Tagged with: Aimovig™, Alder Biopharmaceuticals, Amgen, Eli Lilly, erenumab, FDA, Novartis, Teva

http://twitter.com/share?text="[TITLE]&url=[PERMALINK]
ShareEmail, Linked In, Twitter, Facebook, Google Plus

Back to Top